medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Número 6

<< Anterior Siguiente >>

Rev Invest Clin 2005; 57 (6)


El antígeno carcinoembrionario: a propósito de un viejo conocido

Téllez-Ávila FI, García-Osogobio SM

Idioma: Español
Referencias bibliográficas: 39
Paginas: 814-819
Archivo PDF: 152.57 Kb.


RESUMEN

El antígeno carcinoembrionario (ACE) es una glucoproteína localizada en el polo apical de los enterocitos. Los genes que codifican para el ACE se localizan en el cromosoma 19q13.2. El grupo total está constituido por 29 genes, divididos en tres subgrupos de los cuales se expresan sólo 18. En el individuo sano existen múltiples funciones del ACE que han sido ampliamente estudiadas, su función como molécula de adhesión ha sido la más ampliamente difundida. En pacientes sanos además de expresarse a nivel de colon el ACE se expresa en células de la lengua, esófago, estómago, cervix y próstata. Los pacientes que reciben una mayor utilidad clínica son aquellos con cáncer colorrectal (CCR), cáncer gástrico y cáncer de ovario. Su uso más amplio es en el CCR, actualmente se utiliza como marcador pronóstico, estadiaje, marcador de recurrencia, de respuesta al tratamiento y como indicador de metástasis a nivel hepático. Existen algunas patologías no neoplásicas que causan elevación de las cifras séricas de ACE. Actualmente se estudia al ACE como blanco de inmunoterapia dirigida a tumores que contengan células que expresen esta molécula.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965; 122: 467-81.

  2. Baranov V, Hammarström S. Carcinoembryonic antigen (CEA) and CEA-related cell adhesion molecule 1 (CEACAM1), apically expressed on human colonic M cells, are potential receptors for microbial adhesion. Histochem Cell Biol 2004; 121: 83-9.

  3. Freedman SO. Antigens in tumours. In: Symington T, Carter RL (Ed.). Scientific Foundations of Oncology. 1a Ed. Chicago: William Hainemann Medical Books; 1976, pp. 509-11.

  4. Hammarström S. The carcinoembryonic antigen CEA family: structures, suggested functions and expression in normal and malignant tissues. Sem Cancer Biol 1999; 9: 67-81.

  5. Olsen A, Teglund S, Nelson D, Gordon L, Copeland A, Georgescu A, Carrano A, Hammarström S. Gene organization of the pregnancy-specific glycoprotein region on human chromosome 19: Assembly and analysis of a 700-kb cosmid contig spanning the region. Genomics 1994; 23: 659-68.

  6. Beauchemin N, Draber P, Dveksler G, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res 1999; 252: 243-9.

  7. Crawford N, Colliver D, Galandiuk S. Tumors markers and colorectal cancer: Utility in management. J Surg Oncol 2003; 84: 239-48.

  8. Öbrink B. CEA adhesion molecules: multifunctional proteins with signal-regulatory properties. Curr Opin Cell Biol 1997; 9: 171-7.

  9. Hostetter RB, Augustus LB, Mankarious R, Chi KF, Fan D, Toth C, Thomas P, Jessup JM. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 1990; 82(5): 380-5.

  10. Hostetter RB, Campbell DE, Chi KF, Kerckhoff S, Cleary KR, Thomas P, Jessup JM. Carcinoembryonic antigen enhances metastatic potential of human colorectal carcinoma. Arch Surg 1990; 125(3): 300-4.

  11. Matsuoka Y, Matsuo Y, Okamoto N, Kuroki M, Ikehara Y. Highly effective extraction of carcinoembryonic antigen with phosphatidylinositol-specific phospholipase C. Tumor Biol 1991; 12: 91-8.

  12. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002; 20: 2197-207.

  13. Hammarström S, Baranov V. Is there a role for CEA in innate immunity in the colon? Trends Microbiol 2001; 9: 119-25.

  14. Bast RC, Ravdin P, Hayes DF, et al. 2000 update of recommendations or the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.

  15. Longo W, Johnson F. The preoperative assesment and postopera-tive surveillance of patents with colon and rectal cancer. Surg Clin North Am 2002; 82(5): 1091-108.

  16. Walsh J, Terdiman J. Colorectal cancer screening. JAMA 2003; 289(10): 1288-96.

  17. Wanebo HL, Rao B, Oettgen H, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 299(9): 448-51.

  18. Dixon MR, Haukoos JS, Udani SM, Naghi JJ, Arnell TD, Kumar RR, Stamos MJ. Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg 2003; 138(9): 962-6.

  19. Lindmark G, Bergström R, Pählman L, Glimelius B. The association of preoperative serum tumor markers with Duke’s stage and survival in colorectal cancer. Br J Cancer 1995; 71: 1090-4.

  20. Fletcher RH. Carcinoembryonic antigen. Ann Int Med 1986; 104: 66-73.

  21. Wiratkapun S. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum 2001; 44(2): 231-5.

  22. Sturgeon C. Practice guidelines for tumor marker use in the clin-ic. Clin Chem 2002; 48: 1151-9.

  23. Compton CC, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer prognostic factors consensus conference: Colorectal Working Group. Cancer 2000; 88(7): 1739-57.

  24. Hammond MEH, Fitzgibbons PL, Compton CC, Grignon DJ, et al. College of American Pathologist conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Arch Pathol Lab Med 2000; 124: 958-65.

  25. Eche N, Pichon MF, Quillien V, Gory-Delabaere G, Riedinger JM, Basuyau JP, Daver A, Buecher B, Conroy T, Dieu L, Bidart JM, Deneux L. Groupe de travail Nicole Eche (coordonnateur), oncobiologiste. Standards, options and recommendations for tumor markers in colorectal cancer. Bull Cancer 2001; 88(12): 1177-206.

  26. European Group for Tumors Markers (EGTM). Consensus recommendations. Anticancer Res 1999; 19: 2785-820. Http://egtm.web.med.uni-muenchen.de (acceso junio/05).

  27. Sorbye H, Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitor-ing and guidelines. J Clin Oncol 2003; 21(23): 4466-7.

  28. Meyerhardt J, Mayer R. Follow-up strategies after curative resection of colorectal cancer. Seminars in Oncology 2003; 30(3): 349-60.

  29. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H, Haglund C. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol 2004; 25(5-6): 228-34.

  30. Graham RA, Wang S, Catalano PJ, et al. Postsurgical surveillance of colon cancer: prelimnary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998; 228: 59-63.

  31. Pietra N, Costi R, Ouchemi C, Peracchia A. Role of follow-up in the management of local recurrence of colorectal cancer. Dis Colon Rectum 1998; 41: 1127-33.

  32. Bruinvels DJ, Stiggelbout AM, Kievit J, Habbema DF, Van de Velde CH. Follow-up of patients with colorectal cancer, a meta-analysis. Ann Surg 1994; 219: 174-82.

  33. Marshall JL. Carcinoembryonic antigen-based vaccines. Semin Oncol 2003; 30(Suppl 8): 30-6.

  34. Marshall JL, Tsang K, Arlen P, et al. Phase I trial to determinate the toxicity and immunologic efficacy of the addition of GM-CSF (GM) and IL-2 to the combination of vaccinia-CEA (V) and ALVAC-CEA (A) administered as a prime and boost in patients with advanced CEA-bearing cancers. Proc Am Soc Clin Oncol 2001; 20(Abstr 1087): 272A.

  35. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, Mellstedt H, et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 2004; 10(10): 3273-81.

  36. Garambois V, Glaussel F, Pèlegrin A, et al. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for Radioimmunetherapy (RIT) of colorectal cancers. BMC Cancer 2004; 4: 75-85.

  37. Schwegler C, Dorn-Beineke A, Nittka S, Neumaier M. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking Tolerance to Carcinoembryonic Antigen (CEA) in CEA-Transgenic Mice. Cancer Res 2005; 65(5): 1925-33.

  38. Kerbrat P, Lhommé C, Fervers B, Thomas L, Tournemaine N, et al. Standars, options and recommendations: ovarian cancer. Electronic J Oncol 2001; 1: 32-42. http://www.elecjoncol.org (acceso abril/05)

  39. Abdalla EK, Ahmad SA. Gastric cancer. In: Feig B, Berger D, Fuhrman G. The M. D. Anderson surgical oncology Handbook. 3rd Ed. Houston: Lippincott Williams Wilkins; 2003, pp. 158-92.




2020     |     www.medigraphic.com